A5068185628- Renal Transplantation Outcomes and Treatments
- Neurological Complications and Syndromes
- Pharmacological Effects and Toxicity Studies
- Transplantation: Methods and Outcomes
- Renal Diseases and Glomerulopathies
- HIV/AIDS drug development and treatment
- Hepatitis C virus research
- Statistical Methods in Clinical Trials
- Biochemical and Molecular Research
- Liver Diseases and Immunity
- Liver Disease and Transplantation
- Renal and Vascular Pathologies
- Cancer Treatment and Pharmacology
- Pharmacogenetics and Drug Metabolism
- Organ Transplantation Techniques and Outcomes
- Artificial Intelligence in Healthcare
- Potassium and Related Disorders
- Healthcare Systems and Practices
- Bipolar Disorder and Treatment
- Colorectal Cancer Treatments and Studies
- Chemotherapy-related skin toxicity
- Global Public Health Policies and Epidemiology
- Hematopoietic Stem Cell Transplantation
- Nutritional Studies and Diet
- Analytical Methods in Pharmaceuticals
Université de Limoges
2013-2025
Inserm
2011-2025
Fédération Hospitalo-Universitaire, Paris Center for Microbiome Medicine
2020
Centre Hospitalier Universitaire de Limoges
2009
Mycophenolic acid (MPA), the active metabolite of immunosuppressant mycophenolate mofetil is primarily metabolized by glucuronidation. The nature UDP-glucuronosyltransferases (UGTs) involved in this pathway still debated. present study aimed at identifying unambiguously UGT isoforms production MPA-phenyl-glucuronide (MPAG) and MPA-acylglucuronide (AcMPAG). A liquid chromatography-tandem mass spectrometry method allowing identification determination metabolites mycophenolic was developed....
The aim of this study was to develop maximum a posteriori probability (MAP) Bayesian estimators mycophenolic acid (MPA) pharmacokinetics (PK) capable accurately estimating the MPA interdose AUC in renal transplant patients using limited number blood samples. individual plasma concentration-time profiles 44 adult kidney recipients were retrospectively studied: 24 de novo patients, 2 obtained on day 7 and 30 after transplantation, 20 stable 1 profile period (>3 months). assayed by liquid...
We report a feasibility study based on our large-scale experience with mycophenolate mofetil dose adjustment mycophenolic acid interdose area under the curve (AUC) in renal transplant patients.Between 2005 and 2010, 13,930 requests for 7090 different patients (outside any clinical trial) were posted by more than 30 transplantation centers free, secure web site recommendations using three plasma concentrations Bayesian estimation.This retrospective showed that 1) according to consensually...
A time–to–event model was developed to study the predictive factors of immunosuppressive efficacy in renal transplant patients and investigate longitudinal calcineurin inhibitor (CNI) mycophenolic acid (MPA) coexposures patient characteristics as potential covariates. The end point included acute rejection (AR), graft loss, death. Data from 222 were analyzed: 23 events observed 126 receiving cyclosporine compared with 15 96 tacrolimus (P = 0.61) first 2 years posttransplantation. Each...
Tacrolimus is an immunosuppressant widely used in transplantations requiring mandatory concentration-controlled dosing to prevent acute rejection or adverse effects, including new-onset diabetes mellitus (NODM). However, no relationship between NODM and tacrolimus exposure has been established. This study aimed evaluate the cumulative occurrence.A total of 452 kidney transplant patients were included this study. Sixteen developed during first 3 months after transplant. We considered all...
Aim To compare the pharmacokinetics of mycophenolic acid when given with either ciclosporin or sirolimus, and investigate in vitro potential effect ciclosporin, tacrolimus everolimus on metabolism. Methods In renal transplant patients mycophenolate mofetil combination ( n = 19) sirolimus 12), concentration‐time profiles acid, mycophenolic‐acid‐phenyl‐glucuronide, mycophenolic‐acid‐acyl‐glucuronide mycophenolic‐acid‐phenyl‐glucoside were determined at one month post‐transplant. The...
This study was designed to compare the enzyme multiplied immunoassay technique (EMIT) and a specific ;liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for determination of mycophenolic acid (MPA) concentrations in plasma samples collected from renal transplant patients receiving mycophenolate mofetil association with sirolimus corticosteroids. Ten-point blood concentration-time profiles, between pre-dose (C0) 9-hour post-dose, were obtained on day 7, 14, months 1, 2, 3...
Most predictive models and scores of graft survival in renal transplantation include factors known before transplant or at the end first year. They cannot be updated thereafter, even patients developing donor-specific anti-HLA antibodies acute rejection.We developed a conditional adjustable score for prediction failure (AdGFS) up to 10 years post-transplantation 664 kidney patients. AdGFS was externally validated calibrated 896 patients.The final model included five baseline (pretransplant...
A new mycophenolate (MPA) assay based on the enzymatic activity of recombinant type II inosine monophosphate dehydrogenase (the pharmacological target MPA) with excellent correlation high-performance liquid chromatography has recently been released for measurement MPA plasma levels. This study aimed to (1) compare this tandem mass spectrometry (LC-MS/MS) pharmacokinetic (PK) studies in different populations allograft recipients given mofetil, (2) develop specific Bayesian estimators...
Identification of patients at risk kidney graft loss relies on early individual prediction failure. Data from 616 transplant recipients with a follow-up least one year were retrospectively studied. A joint latent class model investigating the impact serum creatinine (Scr) time-trajectories and onset de novo donor-specific anti-HLA antibody ( dn DSA) survival was developed. The capacity to calculate predicted probabilities failure over time evaluated in 80 independent patients. classified...
Renal failure is predictive of mortality in the early postliver-transplantation period and calcineurin inhibitors toxicity a main challenge. Our aim to assess impact longitudinal tacrolimus exposure (TLE) other variables on chronic kidney disease (CKD)-free 1-year-survival.Retrospective data consecutive patients transplanted between 2011 2016 treated with were collected. TLE all relevant pre- post-liver transplantation (LT) factors CKD tested included time-to-event model. was defined by...